Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity

Thomas Pfeiffer, Stephanie Hyde, Shalini Shenoy, Melissa Mavers, Robert J. Hayashi, Feng Gao, Lisa Madden, Troy Quigg, Michael J. Eckrich, Sima Bhatt, Jeffrey J. Bednarski

Blood (2024) 144 (Supplement 1): 375.

https://doi.org/10.1182/blood-2024-194650

Published: 2024

Journal Articles

Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages

Carol Fries Simpson, Lik Wee Lee, Hongyue Wang, Diana G. Adlowitz, Philip Rock, Brent L. Wood, Rachel E. Rau, Kara L. Davis, Anne Angiolillo, Meenakshi Devidas, David T. Teachey, Karen R Rabin, Birte Wistinghausen, Donald Barkauskas, Robert J. Hayashi, Richard Burack, Carl E Allen, Michelle L. Hermiston, Ilan R. Kirsch

Blood (2024) 144 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2024-201634

Published: 2024

Journal Articles

Successful Allogenic Stem Cell Transplantation Using Radiation-Free Reduced Intensity Conditioning in Idiopathic Pediatric Severe Aplastic Anemia - a Single Center Experience

Mithra Lakshmi Narasimhan, Irem Eldem, David B Wilson, Ginny Schulz, Robert J Hayashi, Shalini Shenoy

Blood (2024) 144 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2024-206543

Published: 2024

Journal Articles

Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma

Blood (2024) 144 (Supplement 1): 313.

https://doi.org/10.1182/blood-2024-203827

Published: 2024

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children's Oncology Group (COG) Studies AALL0434 and AALL1231

Susan I. Colace, Meenakshi Devidas, Zhiguo (Bruce) Chen, Robert J. Hayashi, Brent L. Wood, Natia Esiashvili, Samir Patel, Andrew J Carroll, Nyla A. Heerema, Barbara Asselin, Karen R. Rabin, Patrick A. Zweidler-McKay, Elizabeth A. Raetz, Mignon L. Loh, Naomi J. Winick, William L. Carroll, David T. Teachey, Stuart S. Winter, Kimberly P. Dunsmore

Blood (2023) 142 (Supplement 1): 517.

https://doi.org/10.1182/blood-2023-190141

Published: 2023

Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Blood (2022) 140 (Supplement 1): 6387–6389.

https://doi.org/10.1182/blood-2022-159694

Published: 2022

Journal Articles

A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 1722–1723.

https://doi.org/10.1182/blood-2022-165233

Published: 2022

Journal Articles

Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3487.

https://doi.org/10.1182/blood-2021-151837

Published: 2021

Journal Articles

Estimated Late Health Outcomes in Children Newly Diagnosed with Mature B-Cell Non-Hodgkin Lymphoma Treated with Contemporary LMB Chemotherapy Based upon Similarly Treated Participants in the Childhood Cancer Survivor Study (CCSS)

Matthew J. Ehrhardt, MD MS, Yan Chen, MMath, John Sandlund, MD, Elizabeth C. Bluhm, MD, Robert J. Hayashi, MD, Wendy M. Leisenring, ScD, Monika L. Metzger, MD, Kirsten K. Ness, PhD, Kevin R. Krull, PhD, Kevin C. Oeffinger, MD, Leslie L. Robison, PhD, Yutaka Yasui, PhD, Gregory T. Armstrong, MD MSCE, Melissa M. Hudson, MD, Daniel A. Mulrooney, MD

Blood (2016) 128 (22): 3609.

https://doi.org/10.1182/blood.V128.22.3609.3609

Published: 2016

Journal Articles

Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434

Stuart S. Winter, MD, Meenakshi Devidas, PhD, Si Chen, MS, Barbara Asselin, MD, William L. Carroll, MD, Brent L Wood, MD PhD, Natia Esiashvili, MD, Briegel J Nikki, PharmD, Robert J. Hayashi, MD, Mignon L. Loh, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Elizabeth Raetz, MD, Naomi J. Winick, MD, Stephen P. Hunger, MD, Kimberly P. Dunsmore, MD

Blood (2015) 126 (23): 794.

https://doi.org/10.1182/blood.V126.23.794.794

Published: 2015

Journal Articles

Cognitive, Behavior and Academic Problems in Adolescent Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from the Childhood Cancer Survivor Study

Lisa M Jacola, PhD, Kim Edelstein, PhD CPsych, Wei Liu, PhD, Ching-Hon Pui, MD, Robert J. Hayashi, MD, Nina Kadan-Lottick, MD MSPH, Deokumar Srivastava, PhD, Tara O Henderson, MDMPH, Leslie L. Robison, PhD MPH, Gregory T. Armstrong, MD MSCE, Kevin R. Krull, PhD

Blood (2015) 126 (23): 877.

https://doi.org/10.1182/blood.V126.23.877.877

Published: 2015

Journal Articles

Designated Donor Program Enrollment Does Not Affect Red Blood Cell Alloimmunization Rates in Children with Sickle Cell Disease on Chronic Transfusion Therapy

Ronald Jackups, MD PhD, Debbie Woods, RN, MSN, CPNP, Robert J. Hayashi, MD, Monica L. Hulbert, MD

Blood (2014) 124 (21): 4291.

https://doi.org/10.1182/blood.V124.21.4291.4291

Published: 2014

Journal Articles

Chronic Manual Exchange Transfusions Compared with Erythrocytapheresis in Children and Teens with Sickle Cell Disease

Debbie Woods, RN, MSN, CPNP, Robert J. Hayashi, MD, Melanie E. Fields, MD, Monica L. Hulbert, MD

Blood (2014) 124 (21): 4927.

https://doi.org/10.1182/blood.V124.21.4927.4927

Published: 2014

Journal Articles

Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

Elizabeth C. Bluhm, Cécile Ronckers, Robert J. Hayashi, Joseph P. Neglia, Ann C. Mertens, Marilyn Stovall, Anna T. Meadows, Pauline A. Mitby, John A. Whitton, Sue Hammond, Joseph D. Barker, Sarah S. Donaldson, Leslie L. Robison, Peter D. Inskip

Blood (2008) 111 (8): 4014–4021.

https://doi.org/10.1182/blood-2007-08-106021

Published: 2008

Includes: Supplemental data

Journal Articles

Cause-Specific Mortality and Second Cancer Incidence after Non-Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study.

Elizabeth C. Bluhm, MD, MPH, Cecile Ronckers, PhD, Robert J. Hayashi, MD, Joseph P. Neglia, MD, MPH, Ann C. Mertens, PhD, Anna T. Meadows, MD, Pauline A. Mitby, MS, Marilyn Stovall, PhD, Leslie L. Robison, PhD, Peter D. Inskip, ScD

Blood (2007) 110 (11): 3579.

https://doi.org/10.1182/blood.V110.11.3579.3579

Published: 2007

NARROW

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity

Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages

Successful Allogenic Stem Cell Transplantation Using Radiation-Free Reduced Intensity Conditioning in Idiopathic Pediatric Severe Aplastic Anemia - a Single Center Experience

Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children's Oncology Group (COG) Studies AALL0434 and AALL1231

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease

Estimated Late Health Outcomes in Children Newly Diagnosed with Mature B-Cell Non-Hodgkin Lymphoma Treated with Contemporary LMB Chemotherapy Based upon Similarly Treated Participants in the Childhood Cancer Survivor Study (CCSS)

Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434

Cognitive, Behavior and Academic Problems in Adolescent Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from the Childhood Cancer Survivor Study

Designated Donor Program Enrollment Does Not Affect Red Blood Cell Alloimmunization Rates in Children with Sickle Cell Disease on Chronic Transfusion Therapy

Chronic Manual Exchange Transfusions Compared with Erythrocytapheresis in Children and Teens with Sickle Cell Disease

Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

Cause-Specific Mortality and Second Cancer Incidence after Non-Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only